IN2012DN03180A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03180A
IN2012DN03180A IN3180DEN2012A IN2012DN03180A IN 2012DN03180 A IN2012DN03180 A IN 2012DN03180A IN 3180DEN2012 A IN3180DEN2012 A IN 3180DEN2012A IN 2012DN03180 A IN2012DN03180 A IN 2012DN03180A
Authority
IN
India
Prior art keywords
phenyl
compound
compositions
piperazin
pyrimidin
Prior art date
Application number
Other languages
English (en)
Inventor
Reiner Aichholz
Francesca Blasco
Vincent Bordas
Porta Diana Graus
Vito Guangnano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN03180A publication Critical patent/IN2012DN03180A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3180DEN2012 2009-10-30 2010-10-29 IN2012DN03180A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174619 2009-10-30
PCT/EP2010/066435 WO2011051425A1 (en) 2009-10-30 2010-10-29 N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea

Publications (1)

Publication Number Publication Date
IN2012DN03180A true IN2012DN03180A (enrdf_load_stackoverflow) 2015-09-25

Family

ID=41396002

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3180DEN2012 IN2012DN03180A (enrdf_load_stackoverflow) 2009-10-30 2010-10-29

Country Status (7)

Country Link
US (3) US20120220600A1 (enrdf_load_stackoverflow)
EP (1) EP2493864B1 (enrdf_load_stackoverflow)
KR (1) KR20120101367A (enrdf_load_stackoverflow)
CN (1) CN102596916B (enrdf_load_stackoverflow)
ES (1) ES2524548T3 (enrdf_load_stackoverflow)
IN (1) IN2012DN03180A (enrdf_load_stackoverflow)
WO (1) WO2011051425A1 (enrdf_load_stackoverflow)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
KR102126092B1 (ko) * 2012-03-30 2020-06-24 노파르티스 아게 저인산혈증성 장애의 치료에 사용하기 위한 fgfr 억제제
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
MX387702B (es) 2013-10-25 2025-03-18 Novartis Ag Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
BR112017016817A2 (pt) * 2015-03-25 2018-04-03 Novartis Ag derivados heterocíclicos formilados como inibidores de fgfr4
US20180015079A1 (en) 2015-03-25 2018-01-18 National Cancer Center Therapeutic agent for bile duct cancer
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Fgfr阻害剤の塩
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤の誘導体
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114539258A (zh) * 2020-11-27 2022-05-27 首药控股(北京)股份有限公司 一种fgfr4蛋白激酶抑制剂的多晶型物及其制备方法
CN113185510B (zh) * 2021-04-12 2022-05-13 南京海纳医药科技股份有限公司 一种阿伐曲泊帕杂质的制备方法
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386218A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AU2006326989B2 (en) * 2005-12-21 2011-11-24 Novartis Ag Pyrimidinyl aryl urea derivatives being FGF inhibitors

Also Published As

Publication number Publication date
US20140378468A1 (en) 2014-12-25
CN102596916A (zh) 2012-07-18
WO2011051425A1 (en) 2011-05-05
KR20120101367A (ko) 2012-09-13
ES2524548T3 (es) 2014-12-10
CN102596916B (zh) 2015-06-17
US20160102062A1 (en) 2016-04-14
US20120220600A1 (en) 2012-08-30
EP2493864B1 (en) 2014-10-01
EP2493864A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
IN2012DN03180A (enrdf_load_stackoverflow)
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
UA99833C2 (en) Pyrimidinyl pyridazinone derivates
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MY150136A (en) Picolinamide derivatives as kinase inhibitors
EA201071320A1 (ru) Активаторы глюкокиназы
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX2009012708A (es) Derivados de piridazinona.
WO2007024921A3 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
MX2009004807A (es) Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2010007391A (es) Antagonistas de trpa1.
SG10201406300YA (en) L-ornithine phenyl acetate and methods of making thereof
MX2010007392A (es) Antagonistas de trpa1.
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2010002191A (es) Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2011007165A (es) Derivados de piridazinona.
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
MX2007006284A (es) Acidos biariloximetilarenocarboxilicos.